RAB3GAP2

Across TCGA pan-cancer cohorts, RAB3GAP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RAB3GAP2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RAB3GAP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RAB3GAP2 expression acts as an unfavorable survival marker, although some lineages such as GBM and UCEC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where RAB3GAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.381	0.951	.006	15	view →
LSCC	DFS	Quartile	II,III,IV	0.383	0.856	.004	8	view →
LUAD	OS	Median	All	0.607	0.950	.003	6	view →
GBM	OS	Median	All	0.940	0.776	.008	5	view →
UCEC	OS	Median	All	0.964	0.858	.036	2	view →
CCRCC	DFS	Tertile	II,III,IV	1.000	0.828	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RAB3GAP2–PDAC (OS)

Open the PDAC breakdown →